Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Moodys
McKinsey
McKesson
Express Scripts
AstraZeneca

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,696,084

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,696,084 protect, and when does it expire?

Patent 6,696,084 protects TRIGLIDE and is included in one NDA.

This patent has forty patent family members in thirteen countries.

Summary for Patent: 6,696,084
Title: Spray drying process and compositions of fenofibrate
Abstract:The present invention relates to a novel spray drying process for the preparation of pharmaceutical compositions containing small particles of phospholipid-stabilized fenofibrate. This invention also relates to spray dried powdered compositions prepared according to this process, and to dosage forms of fenofibrate (capsules, tablets, powders, granules, and dispersions) prepared from these powdered compositions. The powdered compositions and dosage forms are useful in the treatment of dyslipidemia and dyslipoproteinemia and have the advantage that they provide reduced in vivo variability in the bioavailability of fenofibrate active species among fed and fasted patients when administered orally.
Inventor(s): Pace; Gary W. (Winchester, MA), Mishra; Awadesh K. (Quebec, CA), Snow; Robert A. (West Chester, PA), Parikh; Indu (Durham, NC), Guivarc'h; Pol-Henri W. (Quebec, CA)
Assignee: RTP Pharma Inc. (Durham, NC)
Application Number:09/838,593
Patent Claim Types:
see list of patent claims
Composition; Process; Use; Dosage form; Formulation;

Drugs Protected by US Patent 6,696,084

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Skyepharma Ag TRIGLIDE fenofibrate TABLET;ORAL 021350-001 May 7, 2005 DISCN No No   Start Trial   Start Trial Y Y A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM   Start Trial
Skyepharma Ag TRIGLIDE fenofibrate TABLET;ORAL 021350-002 May 7, 2005 DISCN Yes No   Start Trial   Start Trial Y Y A METHOD OF TREATING DYSLIPIDEMIA AND DYSLIPOPROTEINEMIA USING A DOSAGE FORM THAT CAN PROVIDE AN EFFECTIVE AMOUNT OF FENOFIBRATE TO A PATIENT IN A FASTED STATE WHICH IS AT LEAST 90% OF THE AUC AMOUNT PROVIDED BY THE DOSAGE FORM   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,696,084

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 357216   Start Trial
Austria 367802   Start Trial
Austria 522211   Start Trial
Australia 2001259099   Start Trial
Australia 2001262945   Start Trial
Australia 2003225285   Start Trial
Australia 2007201953   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Baxter
Express Scripts
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.